OBJECTIVES

To compare the clinical efficacy, safety and economy of domestic and original tigecycline for injection.

METHODS

A total of 1203 patients using generic tigecycline （Zetan, produced by Jiangsu Hausen,China）or original tigecycline（Taige, produced by Wyeth, USA） were retrospectively collected from May 1, 2018 to May 1, 2020 in a large tertiary hospital in Sichuan Province. According to the inclusion and exclusion criteria, 265 effective patients were included, including 199 patients in Zetan group and 66 patients in Taige group. Two groups of patients were subjected to propensity score matching (PSM) using the 1:3 nearest neighbor matching method, and the covariate equilibrium samples were obtained. Clinical and microbiological success rates were used to evaluate the efficacy, and the incidence of adverse reactions was used to evaluate the safety. The matched samples were evaluated by chi-square test to evaluate the difference in efficacy and safety between the original and generic drugs. And the economic evaluation is carried out based on the effectiveness and safety results.

RESULTS

After the propensity score matching, the clinical efficacy of Zetan and the Taige group was no significant difference (63.8% VS 59.1%, P=0.8283), and the safety of Taige group was better than Zetan group (20.1% VS 9.1%) , P=0.03608). Since there was no difference in clinical efficacy between the two groups, the cost-minimization analysis was used for economic evaluation. The cost of Zetan group included drugs and adverse reaction treatment costs (11427.03 yuan), and the cost of Taige group only included drugs costs (21416.75 yuan). According to the cost-minimization analysis, the Zetan group is more economical.

CONCLUSIONS

The clinical efficacy of domestic and original research tigecycline for injection is consistent. The safety of the Taige group is better, but in general, domestic drugs are more economical.